Results

Total Results: 1,122 records

Showing results for "diabetes treatment".
Users also searched for: diabetes guidelines

1001. Patient-Centered-Medical-Home Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/patient-centered-medical-home_executive.pdf
      July 01, 2012 - PCMH.17 Interventions based on the chronic care model (CCM) and focused on single conditions such as diabetes … care system.25-28 The goal is to improve the care of patients across the continuum of prevention and treatment … Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. … Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. … Diabetes Care. 2005;28(2):337-442. PMID: 15677789. 6. Nolte E, McKee CM.

1002. Systematic Review of Breastfeeding Programs and Policies, Breastfeeding Uptake, and Maternal Health Outcomes in Developed Countries (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/breastfeeding_research-protocol.pdf
      January 01, 2020 - breastfeeding or a shorter duration of breastfeeding) was associated with a reduced risk of type 2 diabetes … , cardiovascular outcomes (e.g., stroke, myocardial infarction), postpartum weight change, type 2 diabetes … Postpartum depression, postpartum weight change, breast cancer, ovarian cancer, osteoporosis, type 2 diabetes … used, method of handling dropouts and missing data, validity and reliability of outcome measures, and treatment … Criteria diabetes, hypertension, cardiovascular outcomes (e.g., stroke, myocardial infarction)

1003. Nephropathy-Contrast-Induced Research-Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/nephropathy-contrast-induced_research-protocol.pdf
      October 01, 2013 - coronary computed tomograms (CT), cerebral or cardiac or peripheral vascular angiograms, and radiologic therapeutic … groups, regardless of IV contrast medium type, diagnostic criteria used for AKI, or if the patient had diabetes … increasing prevalence of populations vulnerable to CIN (i.e., people having chronic kidney disease, diabetes … include abstracts from the following professional society meetings: The Trans-catheter Cardiovascular Therapeutics … Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury - a systematic

1004. Smoking-Pregnancy-Infants Research-Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/smoking-pregnancy-infants_research-protocol.pdf
      March 11, 2013 - [Smoking behavior during pregnancy of women with type 1 or gestational diabetes]. … [Pregnancy and nicotine substitution treatments: what to do?]. … [Nicotine replacement therapies during pregnancy: what do we know about the balance between benefits … [Weight cycling during treatment of obese women]. … [Screening, diagnosis and management of diabetes mellitus and diabetic complications].

1005. Closing the Quality Gap Series: Measuring Outcomes of Care for Persons With Disabilities | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/disabilities-quality-improvement-outcomes/research-protocol
      December 01, 2019 - which are manifestations of disease processes, and disabilities that are iatrogenically acquired from treatments … Preventive Services Task Force) Urinary tract infections Pressure ulcers Uncontrolled diabetes … Diabetes complications Bacterial pneumonia Asthma Gastroenteritis Hypertension Obesity … Literature We will search MEDLINE, EPOC (for organizational quality improvement efforts), PEDRO (physical therapy … Physical Therapy 2006, 86(5):726-734 Definition of Terms The following are widely used definitions

1006. Asthma-Provider-Adherence Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/asthma-provider-adherence_executive.pdf
      May 01, 2013 - Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments … patients in practice with asthma “prophylaxis” after one year as compared with practices provided with diabetes … asthma severity, or high health care utilizers) may lead to identification of novel preventive and therapeutic … Inadequate therapy for asthma among children in the United States. … Improving drug therapy for patients with asthma-part 2: Use of antiasthma medications.

1007. Cancer-Drugs-Utilization-Cost Research (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization-cost_research.pdf
      January 01, 2011 - Since, biologics have been developed to treat a variety of conditions other than diabetes, such as … marketplace.10 Further, the development pipeline contains numerous biologics that promise novel anticancer therapies … The use of biologics in cancer therapy. US Pharmacist 2010;35(3) (Oncology suppl):4-7. 10. … Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-137. 11. … Managing the expanded use of biologics across therapeutic areas: an example from B-cell targeted therapies

1008. Healthcare Delivery of Clinical Preventive Services for People with Disabilities (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/people-with-disabilities-protocol.pdf
      January 16, 2024 - (BRFSS) indicates people with disabilities are also more likely to have depression (42% vs. 12%), diabetes … colorectal cancer, depression, HIV infection, hypertension, intimate partner violence, osteoporosis, diabetes … Cancer detection, diagnosis, and treatment for adults with disabilities. … Blood pressure screening, control, and treatment for patients with developmental disabilities in general … postmenopausal women younger than 65 years at increased risk of osteoporosis Prediabetes and Type 2 Diabetes

1009. Cannabis-2023-Surv-Rep-1-App-F (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
      January 01, 2023 - Intervention C Intervention C, Dose Received (Mean) Intervention D Intervention D, Dose Received (Mean) Treatment … Previous treatment with weak opioid: 42 vs. 38 Previous treatment with strong opioid: 19 vs. 11 96 71 … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments

1010. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
      January 01, 2023 - Intervention C Intervention C, Dose Received (Mean) Intervention D Intervention D, Dose Received (Mean) Treatment … Previous treatment with weak opioid: 42 vs. 38 Previous treatment with strong opioid: 19 vs. 11 96 71 … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments

1011. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
      January 01, 2022 - Intervention C Intervention C, Dose Received (Mean) Intervention D Intervention D, Dose Received (Mean) Treatment … Previous treatment with weak opioid: 42 vs. 38 Previous treatment with strong opioid: 19 vs. 11 96 71 … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments

1012. Cannabis-2022-Surv-Rep-3-Tables-F1-4 (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-tables-F1-4.xlsx
      January 01, 2022 - Intervention C Intervention C, Dose Received (Mean) Intervention D Intervention D, Dose Received (Mean) Treatment … Previous treatment with weak opioid: 42 vs. 38 Previous treatment with strong opioid: 19 vs. 11 96 71 … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments … NA NA NA NA NA NA NR NR NR NR NR NR NR NR NR NR NA NA NA NA NA NA NA NA NA NA Unclear Unclear NA NA Treatments

1013. Development and Usability Testing of EPC Evidence Review Dissemination Summaries for Health Systems Decisionmakers (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-usability-testing.pdf
      November 01, 2018 - Mental Health • Bone and Joint Health • Cancer • Cardiovascular Health and Stroke • Critical Care • Diabetes … drugs are approved as first-line treatments: “[…] who determines that they’re first line treatment …  Studies incorporating therapeutic drug monitoring over long-term periods in naturalistic settings …  Evidence on the effectiveness and safety of combining antipsychotics with other types of therapy … engagement (parent rated), therapeutic alliance (parent rated) Low Training practitioners to use

1014. AHRQ Slide Template 2004 (ppt file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/introduction.ppt
      January 01, 2010 - If patients are choosing between two treatments, CE research does not study treatment 1 versus placebo … but rather compares treatment 1 versus treatment 2. … International-University of North Carolina EPC Pregnancy, developmental delays, and autism Vanderbilt University EPC Diabetes … use and resistance — University of Pennsylvania School of Medicine Therapeutic medical devices — Weill … New Jersey Therapies for older adults and the effects of aging — University of Iowa Pediatric therapeutics

1015. AHRQ Slide Template 2004 (ppt file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/introduction.ppt
      January 01, 2010 - If patients are choosing between two treatments, CE research does not study treatment 1 versus placebo … but rather compares treatment 1 versus treatment 2. … International-University of North Carolina EPC Pregnancy, developmental delays, and autism Vanderbilt University EPC Diabetes … use and resistance — University of Pennsylvania School of Medicine Therapeutic medical devices — Weill … New Jersey Therapies for older adults and the effects of aging — University of Iowa Pediatric therapeutics

1016. Management of High-Need, High-Cost Patients: A Realist and Systematic Review | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/high-utilizers-health-care/protocol
      May 01, 2020 - KQ 3: Any intervention or treatment as usual.   … Patient health behavior (e.g., treatment adherence, empowerment, knowledge, self-care). … by limiting them to specific conditions or combinations of conditions (e.g., cardiovascular disease, diabetes … DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12(6):355‐62. … Mesh]) OR "multimorbidity" [MeSH] Sort by: Best Match  100740 #3 Search ((((((((((((((((((("Diabetes

1017. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pregnancy_hi_impact.pdf
      January 01, 2012 - new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic … purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments … , screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address … CDB-2914 (ulipristal acetate) for treatment of uterine fibroids 2. … and the treatment is potentially more expensive than the current treatment available as well.” 41

1018. Newly Medicare-Eligible Disabled: Data Points #11 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/medicare-eligible-disabled_research.pdf
      June 01, 2011 - chronic conditions: cancer, Alzheimer’s, chronic obstructive pulmonary disease (COPD), depression, diabetes … Among those likely to have complete claims, depres- sion and diabetes were the most common comorbidities … 2.20 Alzheimer’s 1.20 0.74 0.78 0.74 COPD 5.77 9.44 5.53 4.22 Depression 22.92 25.75 18.84 11.81 Diabetes … Methodological issues in the case of administrative claims data to study surveillance after cancer treatment

1019. Evidence-based Practice Center Systematic Review Protocol: Management of High-Need, High-Cost Patients: A Realist and Systematic Review (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/mgmt-hnhc-patients-protocol.pdf
      November 07, 2019 - health care providers and social support systems, which, in turn, could increase adherence to their treatment … as usual, or no comparator intervention KQ 3: Any intervention or treatment as usual KQ 3: No … limiting them to specific conditions or combinations of conditions (e.g., cardiovascular disease, diabetes … DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12(6):355‐62. … Comorbidity"[Mesh]) OR "multimorbidity" [MeSH] Sort by: Best Match 100740 #3 Search ((((((((((((((((((("Diabetes

1020. Crosscutting-Horizon-Scan-High-Impact-1412 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic … purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments … , screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address … Adherence to long-term therapies. … Wirelessly observed therapy in comparison to directly observed therapy for the treatment of tuberculosis